Effects of silybin supplementation on nutrient digestibility, hematological parameters, liver function indices, and liver-specific mi-RNA concentration in dogs.
Canine
Hepatoprotector
Neutraceuticals
Nutrition
Supplement
Sylimarin
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
26 Jun 2021
26 Jun 2021
Historique:
received:
17
01
2021
accepted:
24
05
2021
entrez:
27
6
2021
pubmed:
28
6
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Hepatopathies are an important group of disorders in dogs where proper nutritional care is crucial. Supplementation with a hepatoprotectant like silybin can improve liver function and should not interfere with nutrient digestibility. The purpose of this study was to investigate the effect of both pure silybin and commercial hepatoprotectant on nutrients digestibility, liver function indices and health status in healthy dogs (EXP1). Moreover, the second experiment (EXP2) investigated the effect of commercial hepatoprotectant on liver function tests and liver-associated miRNAs concentration in dogs with idiopathic liver disorder. Nutrient digestibility was not affected by treatment in EXP1. Supplementation did alter the serum fatty acid profile, with no clinical relevance. The levels of liver markers such as ALT, AST and GGT significantly decreased. In EXP2, supplementation with commercial hepatoprotectant containing silybin improved liver function tests. A decrease was observed in liver serum markers such as ALT, AST and miR122 concentration. EXP1 confirmed that silybin (whether pure or as a commercial hepatoprotectant) does not interfere with digestion which subsequently exerts no detrimental effect on dogs' health and metabolism. In EXP2, dietary supplementation with commercial hepatoprotectant containing silybin resulted in a decreased activity of serum liver markers, accompanied by a decrease in the concentration of liver-specific miRNA molecules. Liver function indices were consequently improved. Silybin supplementation can thus serve as an effective therapeutical tool in dogs with hepatopathies.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatopathies are an important group of disorders in dogs where proper nutritional care is crucial. Supplementation with a hepatoprotectant like silybin can improve liver function and should not interfere with nutrient digestibility. The purpose of this study was to investigate the effect of both pure silybin and commercial hepatoprotectant on nutrients digestibility, liver function indices and health status in healthy dogs (EXP1). Moreover, the second experiment (EXP2) investigated the effect of commercial hepatoprotectant on liver function tests and liver-associated miRNAs concentration in dogs with idiopathic liver disorder.
RESULTS
RESULTS
Nutrient digestibility was not affected by treatment in EXP1. Supplementation did alter the serum fatty acid profile, with no clinical relevance. The levels of liver markers such as ALT, AST and GGT significantly decreased. In EXP2, supplementation with commercial hepatoprotectant containing silybin improved liver function tests. A decrease was observed in liver serum markers such as ALT, AST and miR122 concentration.
CONCLUSIONS
CONCLUSIONS
EXP1 confirmed that silybin (whether pure or as a commercial hepatoprotectant) does not interfere with digestion which subsequently exerts no detrimental effect on dogs' health and metabolism. In EXP2, dietary supplementation with commercial hepatoprotectant containing silybin resulted in a decreased activity of serum liver markers, accompanied by a decrease in the concentration of liver-specific miRNA molecules. Liver function indices were consequently improved. Silybin supplementation can thus serve as an effective therapeutical tool in dogs with hepatopathies.
Identifiants
pubmed: 34174886
doi: 10.1186/s12917-021-02929-3
pii: 10.1186/s12917-021-02929-3
pmc: PMC8235871
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Silybin
4RKY41TBTF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
228Références
J Vet Intern Med. 2009 Nov-Dec;23(6):1142-50
pubmed: 19780929
Res Vet Sci. 2016 Dec;109:142-148
pubmed: 27892863
Sci Rep. 2017 Sep 12;7(1):11315
pubmed: 28900244
Exp Mol Pathol. 2014 Feb;96(1):98-107
pubmed: 24368110
Vet J. 2018 Feb;232:27-32
pubmed: 29428088
Physiol Res. 2019 Nov 22;68(Suppl 1):S39-S50
pubmed: 31755289
J Hepatol. 2003 Sep;39(3):333-40
pubmed: 12927918
J Vet Intern Med. 2019 May;33(3):1173-1200
pubmed: 30844094
Annu Rev Immunol. 1993;11:165-90
pubmed: 8386517
J Vet Intern Med. 2011 Jul-Aug;25(4):838-45
pubmed: 21689156
BMC Genomics. 2016 Aug 17;17:649
pubmed: 27535741
Gastroenterology. 2003 Jan;124(1):97-104
pubmed: 12512034
Gastroenterology. 2010 Feb;138(2):671-81, 681.e1-2
pubmed: 19782083
Iran J Basic Med Sci. 2011 Jul;14(4):308-17
pubmed: 23492971
Biomed Pharmacother. 2020 Mar;123:109721
pubmed: 31865143
J Vet Pharmacol Ther. 2008 Oct;31(5):431-6
pubmed: 19000262
J Anim Physiol Anim Nutr (Berl). 2018 Feb;102(1):297-307
pubmed: 28276099
Int J Mol Sci. 2018 Jan 16;19(1):
pubmed: 29337905
Hepatology. 1996 Jun;23(6):1334-40
pubmed: 8675148
J Small Anim Pract. 2010 Nov;51(11):566-72
pubmed: 20973784
J Nutr Sci. 2014 Dec 30;3:e63
pubmed: 26101631
Meat Sci. 2015 Oct;108:32-6
pubmed: 26017245
J Am Anim Hosp Assoc. 2016 Jan-Feb;52(1):1-7
pubmed: 26606205
Vet Rec. 2015 Apr 25;176(17):435
pubmed: 25552475
J Small Anim Pract. 2011 Jul;52(7):385-96
pubmed: 21649660
Immunol Today. 1994 Jan;15(1):19-26
pubmed: 7907877
J Vet Intern Med. 2016 Nov;30(6):1816-1823
pubmed: 27859748
Molecules. 2019 Apr 19;24(8):
pubmed: 31010179
Compend Contin Educ Vet. 2009 Sep;31(9):408-10, 412-3; quiz 414
pubmed: 20180206
J Vet Pharmacol Ther. 2010 Feb;33(1):95-9
pubmed: 20444031
J Vet Med Educ. 2016 Winter;43(4):349-358
pubmed: 27295119
J Med Toxicol. 2010 Mar;6(1):22-6
pubmed: 20182837
Crit Rev Food Sci Nutr. 2017 Dec 12;57(18):3850-3859
pubmed: 27171904
Vet Pathol. 2005 Mar;42(2):147-60
pubmed: 15753468
Curr Pathobiol Rep. 2013 Mar;1(1):53-62
pubmed: 23565350
AAPS PharmSci. 2003;5(3):E25
pubmed: 14621960
BMC Vet Res. 2015 Aug 13;11:200
pubmed: 26268360
Res Vet Sci. 2017 Jun;112:161-166
pubmed: 28433933
J Vet Intern Med. 2018 Sep;32(5):1637-1644
pubmed: 30070004
Mol Cell Biochem. 2008 Jun;313(1-2):53-61
pubmed: 18373278
Planta Med. 2002 Nov;68(11):961-5
pubmed: 12451483
Vet Clin North Am Small Anim Pract. 2004 Jan;34(1):67-172, vi
pubmed: 15032126
Parasitol Res. 2005 Dec;97(6):445-51
pubmed: 16151741
Free Radic Biol Med. 2017 Sep;110:240-249
pubmed: 28625483
J Vet Intern Med. 2002 Nov-Dec;16(6):665-8
pubmed: 12465762
Can Vet J. 2010 Jan;51(1):85-8
pubmed: 20357947